You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
|
|---|---|
| Published in |
Breast Cancer Research, January 2014
|
| DOI | 10.1186/bcr3601 |
| Pubmed ID | |
| Authors |
Brent N Rexer, Siprachanh Chanthaphaychith, Kimberly Brown Dahlman, Carlos L Arteaga |
| Abstract |
Despite multiple advances in the treatment of HER2+ breast cancers, resistance develops even to combinations of HER2 targeting agents. Inhibition of PI3K pathway signaling is critical for the efficacy of HER2 inhibitors. Activating mutations in PIK3CA can overlap with HER2 amplification and have been shown to confer resistance to HER2 inhibitors in preclinical studies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 4% |
| Austria | 1 | 1% |
| Australia | 1 | 1% |
| Unknown | 64 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 30% |
| Student > Ph. D. Student | 11 | 16% |
| Student > Bachelor | 7 | 10% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 8 | 12% |
| Unknown | 10 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 17 | 25% |
| Medicine and Dentistry | 16 | 23% |
| Biochemistry, Genetics and Molecular Biology | 15 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Psychology | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 12 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2014.
All research outputs
#17,686,736
of 22,741,406 outputs
Outputs from Breast Cancer Research
#1,540
of 1,894 outputs
Outputs of similar age
#219,168
of 305,708 outputs
Outputs of similar age from Breast Cancer Research
#19
of 27 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,894 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,708 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.